Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
As a health professional, you need the leading dialysis products, renal pharmaceuticals and critical care solutions. Let's work together to find you the tools you need, so you can deliver the best care for patients.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
WALTHAM, MASS. — Oct. 23, 2018 — Fresenius Medical Care North America (FMCNA), the nation’s leading renal care company, today announced the presentation of 71 abstracts at the 2018 American Society of Nephrology’s (ASN) Kidney Week Symposium. The company’s clinical experts demonstrate multiple advances in kidney care that improve patient outcomes, especially around artificial intelligence and connected home therapies.
“We are committed to the highest level of patient care and quality across our entire portfolio of products and services,” said Bill Valle, chief executive officer of Fresenius Medical Care North America. “Through sophisticated machine learning and predictive models, we are finding new and better ways to personalize care that will enhance the patient experience and improve outcomes.”
The annual symposium is the most influential gathering of kidney professionals in the world, drawing more than 13,000 physicians, scientists and healthcare professionals from over 100 countries. It is being held this year from Oct. 23 – 28 at the San Diego Convention Center in San Diego, Calif.
“We are especially excited about our work to improve the connectivity of our home product portfolio that is
Highlights of key Fresenius Medical Care presentations at the 2018 ASN Kidney Week include:
In North America alone, Fresenius Medical Care’s research and quality improvement efforts involve the contributions of more than 1,000 employees. FMCNA collects substantial amounts of data during routine treatments, including data on more than one million patients, more than 300 million dialysis treatments and more than one billion medication administrations and laboratory results.
Fresenius Medical Care North America is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, Fresenius Medical Care North America provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.